Researchers Question Exelixis Patent Play on Cabozantinib

Researchers allege that Exelixis Inc (NASDAQ: EXEL) used a 'trivial' modification to its cabozantinib franchise to product hop past a looming patent cliff, according to Endpoints News; Exelixis shares traded at $51.50, down 2.76%, as of 18:50 GMT on 11 August 2026.

Exelixis Inc (NASDAQ: EXEL) built its modern identity on one molecule. Cabozantinib — sold in kidney, liver and thyroid cancer indications — has been the engine behind the company's revenue, its research budget and, by extension, its share price. Now a group of researchers is arguing that the biotech leaned on a "trivial" modification to that same molecule in order to product hop past a looming patent cliff, a claim laid out in reporting by Endpoints News.

The stock was not enjoying the attention. Exelixis changed hands at $51.50 as of 18:50 GMT on 11 August 2026, down 2.76% from the prior close of $52.96, and near the low end of a $51.46–$53.50 intraday band. That is a heavier move than the broad market managed on the same session, with the S&P 500 proxy SPY off 0.34% at $770.38, the Nasdaq 100 proxy QQQ down 0.50% at $717.23 and the Dow tracker DIA lower by 0.21% at $537.86.

What 'product hopping' actually means

Product hopping is a term of art in pharmaceutical competition law. A branded drugmaker facing the expiry of a patent introduces a reformulated or slightly altered version of the same active ingredient — a new salt, a new tablet, a new dosing schedule — and shifts prescribing to that version before generics arrive for the original. Because a generic can only be substituted at the pharmacy counter for the exact product it copies, the copy launches into a market that has already moved on.

Nothing about a reformulation is inherently improper. Drugmakers reformulate for real reasons: tolerability, absorption, patient adherence, pediatric dosing. The dispute is always about degree. If the change delivers a genuine clinical benefit, it is innovation. If the change is, in the researchers' word, "trivial" — a modification whose main function is to reset the exclusivity clock rather than to help patients — then critics call it evergreening, and it becomes a target for antitrust regulators, payers and academic pharmacy-policy groups.

That is the frame the researchers have placed around Exelixis. The company has not, on the facts available here, conceded any of it, and an academic allegation is not a legal finding. But the argument matters because it goes to the durability of the single revenue line that funds the entire enterprise.

Why one molecule carries this much weight

When chief executive Michael Morrissey presented the company's final 2025 figures earlier this year, the dependence on cabozantinib was impossible to miss. It was the item that funded the operating base and underwrote investor confidence in the equity. Single-asset concentration is common in mid-cap oncology, and it cuts both ways: it makes revenue highly legible and highly leveraged to one legal outcome.

For a company in that position, the exclusivity calendar is not a footnote. It is the discount-rate assumption embedded in every model on the sell side. Push the cliff out and the terminal value expands. Bring it forward and it compresses fast, because there is no second franchise sitting behind the first to absorb the shock. That asymmetry is why patent-strategy stories move biotech share prices more than the underlying legal timeline would suggest — and why a 2.76% single-day decline in a broadly soft but unremarkable tape is worth noticing rather than dismissing.

The audiences that will read this differently

Three constituencies have a stake in how the allegation lands, and none of them will read it the same way.

• Generic manufacturers. Any company preparing a copy of the original formulation cares whether prescribing has already migrated. A successful hop turns a launch into a stranded asset.
• Payers and pharmacy benefit managers. Oncology drugs sit among the most expensive lines on a formulary. Delayed generic entry is a direct budget cost, and payers have grown far more willing to litigate and to publicize.
• Equity holders. For shareholders the calculus is unsentimental. A hop that survives scrutiny protects cash flow. A hop that draws an antitrust challenge or fails in court converts an assumed revenue tail into an open question.

Academic work of this kind rarely changes anything on its own. What it does is supply the evidentiary scaffolding that other parties use later — a competitor's complaint, a state attorney general's inquiry, a congressional letter. The research paper is the cheap part; the litigation it seeds is not.

The tests to watch from here

The near-term questions are procedural rather than dramatic. Does Exelixis respond substantively to the characterization, or treat it as academic commentary? Does any generic filer or payer cite the work in a filing? And when the company next discusses the franchise publicly, does management address the exclusivity runway in more granular terms than before?

Investors should also watch the gap between the narrative and the price. Exelixis traded within a range of $51.46 to $53.50 on the session, so the market absorbed the story without disorder — a repricing, not a rupture. Holders who bought the stock as a cash-generative single-asset oncology name are being asked to underwrite a legal thesis alongside a commercial one, and those two things do not always move together.

The broader evergreening backdrop

The cabozantinib dispute is one instance of a pattern that has drawn steadily more scrutiny across the drug industry: how far a patent estate can be stretched around a molecule that is already generating substantial revenue. Regulators in the United States have shown increasing interest in the mechanics of exclusivity extension, and academic groups have made a specialty of documenting the specific modifications that trigger new patent terms.

For a company whose income statement runs largely through one product, that scrutiny is structural rather than incidental. Exelixis has argued for years that its pipeline will eventually diversify the revenue base. The value of this particular allegation, whatever its legal fate, is that it puts a clock on that ambition. If the cliff arrives on the original schedule rather than the extended one, the diversification story stops being optional.

Key facts

• Stock: Exelixis Inc (NASDAQ: EXEL) at $51.50, -2.76%, as of 18:50 GMT 11 Aug 2026
• Day range: $51.46–$53.50; previous close $52.96
• Allegation: Researchers say a 'trivial' modification to cabozantinib was used to product hop past a patent cliff
• Concentration: Cabozantinib played an outsized role in funding Exelixis, per CEO Michael Morrissey's final 2025 figures

Frequently asked questions

What is cabozantinib and why does it matter to Exelixis?

Cabozantinib is the cancer drug at the center of Exelixis's business. When chief executive Michael Morrissey presented the company's final 2025 numbers earlier this year, the drug's outsized role in funding operations and supporting the share price was clear. Because Exelixis leans so heavily on one molecule, anything affecting its exclusivity carries unusual weight for the company.

What does 'product hopping' mean in pharmaceuticals?

Product hopping describes a branded drugmaker introducing a modified version of a drug — a new formulation, salt or dosing regimen — and shifting prescribing to it before generics of the original arrive. Because pharmacists can only substitute a generic for the exact product it copies, the generic launches into a market that has already migrated, blunting price competition.

How did Exelixis stock react?

Exelixis traded at $51.50 as of 18:50 GMT on 11 August 2026, down 2.76% from the previous close of $52.96, within an intraday range of $51.46 to $51.46–$53.50. That decline was steeper than the broad market, where the S&P 500 proxy fell 0.34%, the Nasdaq 100 proxy 0.50% and the Dow tracker 0.21%.

Is a 'trivial' modification illegal?

Not by itself. Reformulating a drug is lawful and often clinically justified — for tolerability, absorption or adherence. The legal risk arises when a change appears designed mainly to extend exclusivity rather than benefit patients, which can attract antitrust claims from generic manufacturers, payers or regulators. An academic allegation is not a legal finding.

Who else is affected by the outcome?

Generic manufacturers preparing copies of the original formulation, payers and pharmacy benefit managers carrying expensive oncology drugs on their formularies, and Exelixis shareholders whose valuation assumptions depend on how long the cabozantinib revenue stream lasts. Each group has a different financial interest in how quickly generic competition begins.

What should investors watch next?

Whether Exelixis responds substantively to the researchers' characterization, whether any generic filer or payer cites the work in a legal filing or regulatory complaint, and how management describes the exclusivity runway in future public discussion. Also relevant is progress on pipeline diversification, which reduces reliance on a single molecule.

Sources

• Did Exelixis use a 'trivial' modification to its cash cow to product hop past a patent cliff? These researchers think so — Endpoints News

Photo: https://kaboompics.com/ · Pexels Licence — source